NASDAQ: PMN

ProMIS Neurosciences, Inc.

Healthcare | Biotechnology

No licensed closing price on file for PMN. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

ProMIS Neurosciences, Inc. (NASDAQ: PMN) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 07:34 UTC.

What ProMIS Neurosciences, Inc. does

ProMIS has licensed a technology platform designed to develop antibody-based therapies for neurodegenerative diseases and other conditions involving misfolded proteins, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. The company's EpiSelect platform uses computational methods to identify disease-specific epitopes—unique structural features found only on toxic, misfolded proteins—allowing researchers to design antibodies that selectively target disease-causing forms while leaving healthy proteins intact.

Summarized from ProMIS Neurosciences, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for PMN are available in Oxford Ledge.
Open PMN in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-06

2026-10-06Chief Commercial OfficerOption (right to buy)Award80,000—
2026-08-07Chief Development OfficerPurchase2,280$30.3K
2026-05-22Principal Accounting OfficerOption (right to buy)Award18,167—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

Jupiter Topco LLC1,292,757$17.01MNEW
JANUS HENDERSON GROUP PLC1,292,757$16.42MNEW
Deep Track Capital, LP835,655$11.00M0.0%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2024-10-10Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2024-01-03Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2022-09-13Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Promis Neurosciences Q2 Earnings Call Highlights
marketbeat.com2026-08-13
All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy
zacks.com2026-06-12POS
Fewer than five qualifying stories — full tape in the platform →

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for PMN and 5,000+ tickers.

Create a free account — keep PMN

For your agent

GET /api/data?ticker=PMN

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt